Kulakowski E C, Hurst J H, Miller T, Linnoila M, Lovenberg W
Life Sci. 1984 Sep 17;35(12):1329-35. doi: 10.1016/0024-3205(84)90105-x.
CGP 6085 A [4-(5,6-dimethyl-2-benzofuranyl) piperidine HCl], a reported serotonin uptake and MAO (16) inhibitor, is a potent hypothermic agent. The hypothermic action of CGP 6085 A is dose dependent with a maximal reduction in rectal core temperature of greater than 1 degree C within one hour after drug administration. Fluoxetine and citalopram elicit a similar response at equal doses. These results suggest that inhibition of serotonin uptake may produce the hypothermic effect. To assess the in vivo action of CGP 6085 A in inhibiting hypothalamic serotonin uptake, CGP 6085 A (10 mg/kg) was injected one hour prior to injection of 3-hydroxy-4-methyl-alpha-ethyl-phenylethylamine (H75/12), a serotonin depletor. The ability of CGP 6085 A to block the uptake of H75/12 by the 5HT uptake system was indicative of its ability to block serotonin uptake. Pretreatment with p-chlorophenylalanine (pCPA), an inhibitor of serotonin synthesis, resulted in the loss of the hypothermic response to CGP 6085 A. Thus, these data are consistent with the idea that CGP 6085 A may produce its hypothermic response by inhibiting serotonin uptake.
CGP 6085 A [4-(5,6-二甲基-2-苯并呋喃基)哌啶盐酸盐],一种已报道的血清素摄取和单胺氧化酶(16)抑制剂,是一种强效的体温降低剂。CGP 6085 A的体温降低作用呈剂量依赖性,给药后一小时内直肠核心温度最大降低超过1摄氏度。氟西汀和西酞普兰在同等剂量下引发类似反应。这些结果表明,血清素摄取的抑制可能产生体温降低效应。为了评估CGP 6085 A在体内抑制下丘脑血清素摄取的作用,在注射血清素消耗剂3-羟基-4-甲基-α-乙基苯乙胺(H75/12)前一小时注射CGP 6085 A(10毫克/千克)。CGP 6085 A通过5-羟色胺摄取系统阻断H75/12摄取的能力表明其阻断血清素摄取的能力。用血清素合成抑制剂对氯苯丙氨酸(pCPA)进行预处理导致对CGP 6085 A的体温降低反应丧失。因此,这些数据与CGP 6085 A可能通过抑制血清素摄取产生其体温降低反应的观点一致。